---
title: "Clearmind to issue $1,500,000 in convertible promissory notes"
url: "https://aibio.space/news/clearmind-issue-1-500-000-convertible-promissory-notes/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2026-06-01"
section: "Debt Financing"
tickers: "NASDAQ:CMND"
source: "https://www.sec.gov/Archives/edgar/data/1892500/000121390026063494/ea029301301-6k_clearmind.htm"
summary: "The notes carry a $1,500,000 principal amount and a cash purchase price of 90% of principal. The sale falls under an investor agreement amended in April 20"
---

By the aibio.space news desk.

Sources

- [SEC filing](https://www.sec.gov/Archives/edgar/data/1892500/000121390026063494/ea029301301-6k_clearmind.htm)

[CMND](https://aibio.space/companies/clearmind-medicine/)

2026-06-01

# Clearmind to issue $1,500,000 in convertible promissory notes

Tickers [CMND](https://aibio.space/companies/clearmind-medicine/)

The notes carry a $1,500,000 principal amount and a cash purchase price of 90% of principal. The sale falls under an investor agreement amended in April 2026.

## Key facts

- **Company**: Clearmind Medicine Inc. (NASDAQ: CMND)

- **News type**: Debt Financing

- **Primary source**: [SEC filing](https://www.sec.gov/Archives/edgar/data/1892500/000121390026063494/ea029301301-6k_clearmind.htm)

*A city skyline in morning haze. CC0, via rawpixel. The picture shows the field, not the companies named.*

Clearmind Medicine Inc. said in a Form 6-K dated June 1, 2026 that it agreed with a group of investors, called the CLA Investors in the filing, to issue convertible promissory notes with a principal amount of $1,500,000. The aggregate purchase price is payable in cash at 90% of principal, or $1,350,000. The company expects the transaction to close on or about June 1, 2026.

The notes are issued under securities purchase agreements dated September 17, 2025, as amended on April 30, 2026. Under those agreements, the company may sell up to $10,000,000 of promissory notes in total. The filing does not state the interest rate, maturity date, conversion price or security for the new notes, and it does not say what the company will use the proceeds for.

Clearmind is based in Vancouver, British Columbia, and files as a foreign private issuer. The 6-K is signed by Chief Executive Officer Adi Zuloff-Shani. The filing names no placement agent or advisor for the sale.

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

CMND

Clearmind Medicine Inc.

NASDAQ · Canada

Open the starter desk

## More in Debt Financing

Debt Financing

### [Pelthos amends Horizon venture loan, funds Loans E to H and adds Loans I and J](https://aibio.space/news/pelthos-amends-horizon-venture-loan-funds-loans-e-h-adds-loans/)

Oct 30, 2026

Debt Financing

### [Repligen announces $1.0 billion private convertible notes transaction](https://aibio.space/news/repligen-announces-1-0-billion-private-convertible-notes-transaction/)

Oct 30, 2026

Debt Financing

### [FOXO to buy Ludwig Enterprises preferred stock with majority voting power](https://aibio.space/news/foxo-buy-ludwig-enterprises-preferred-stock-majority-voting-power/)

Oct 29, 2026

---
Source page: https://aibio.space/news/clearmind-issue-1-500-000-convertible-promissory-notes/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Clearmind to issue $1,500,000 in convertible promissory notes", 2026-06-01, https://aibio.space/news/clearmind-issue-1-500-000-convertible-promissory-notes/